Bio


Dr. Zhao is a postdoctoral researcher at Stanford University specializing in computational neuroscience, neuroimaging, and integrative multi-omics approaches to brain health. His research integrates supervised and unsupervised machine learning, functional neuroimaging, microbiome sequencing, metabolomics, and large-scale clinical datasets (e.g., Alzheimer's Disease Neuroimaging Initiative and National Health and Nutrition Examination Survey) to investigate how modifiable risk factors such as obesity, diet, and gut dysbiosis contribute to accelerated brain aging, cognitive vulnerability, and psychiatric symptoms.

His work focuses on developing multimodal frameworks that combine functional brain connectivity, cognitive and emotional phenotyping, microbiome profiles, and metabolomic signatures to uncover biological mechanisms underlying early cognitive decline and neuropsychiatric disorders. Through these approaches, Dr. Zhao aims to identify personalized intervention strategies—including dietary modification, microbiome-targeted therapies, and metabolite-guided treatments—to mitigate obesity-related brain aging and reduce the risk of cognitive impairment, Alzheimer's disease, anxiety, and depression.

In addition to translational neuroscience research, Dr. Zhao develops machine learning and computational methods for biomarker discovery, disease prediction, and precision psychiatry. His recent work also explores autonomous AI research agents and self-improving computational systems for large-scale neuroimaging and multi-omics foundational analysis. His publications were in online Nature Mental Health, Molecular Psychiatry, JAMA Network Open. He serves as a peer reviewer for leading journals, including Nature Mental Health, Medical Image Analysis, IEEE Transactions on Medical Imaging, npj Digital Health, and Neuropsychopharmacology.

Professional Education


  • PhD, Lehigh University, Bioengineering (2025)

Stanford Advisors


  • Yu Zhang, Postdoctoral Faculty Sponsor

Research Interests


  • Brain and Learning Sciences
  • Child Development
  • Data Sciences
  • Psychology

All Publications


  • Generalizable structure-function covariation predictive of antidepressant response revealed by target-oriented multimodal fusion NATURE MENTAL HEALTH Tong, X., Zhao, K., Fonzo, G. A., Xie, H., Carlisle, N. B., Keller, C. J., Oathes, D. J., Sheline, Y., Nemeroff, C. B., Trivedi, M., Etkin, A., Zhang, Y. 2025
  • Functional Connectome of Superagers Reveals Early Markers of Resilience and Vulnerability to Alzheimer's Disease. bioRxiv : the preprint server for biology Zhao, K., Xie, H., Fonzo, G. A., Carlisle, N. B., Jacobs, T., Osorio, R. S., Church, A., Lin, F. V., Zhang, Y., ADNI Study Group 2025

    Abstract

    As populations age, identifying the neurobiological basis of cognitive resilience is critical for delaying or preventing Alzheimer's disease (AD). While most older adults experience memory decline, a subset known as superagers (SA) maintains youthful memory into late life, offering a unique window into protective mechanisms against neurodegeneration. Here, we identified a functional connectivity (FC) signature, termed Alzheimer's-resilient connectome (ARC), that robustly differentiates SA from age-matched patients with AD. Using resting-state fMRI in a discovery cohort (N = 290), we identified ARC derived from machine learning classifiers that distinguished SA from AD with high accuracy (AUC = 0.85), and validated the replicability of the ARC in an independent replication cohort (N = 143). ARC involved prefrontal, temporal and insular networks and was strongly associated with brain age. When applied to cognitively unimpaired (CU) adults (discovery cohort: N = 818 and replication cohort: N = 497), ARC-based subtyping revealed SA-like and AD-like subgroups with similar baseline cognitive performance but markedly divergent longitudinal trajectories. SA-like CU individuals showed slower cognitive decline, reduced amyloid-beta accumulation, and lower risk of conversion to mild cognitive impairment and AD, reinforcing the ARC signature as a potential early indicator of resilience. Genome-wide association analysis identified CLYBL and FRMD6 as novel genetic modulators associated with these divergent aging phenotypes. Together, our findings position ARC as a sensitive and generalizable biomarker of resilience, enabling early risk stratification and precision prevention for AD.

    View details for DOI 10.1101/2025.07.20.665707

    View details for PubMedID 40777400

  • Multiband EEG signatures decoded using machine learning for predicting rTMS treatment response in MDD. Journal of affective disorders Arteaga, A., Tong, X., Zhao, K., Carlisle, N. B., Oathes, D. J., Fonzo, G. A., Keller, C. J., Zhang, Y. 2025: 119483

    Abstract

    Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment for major depression disorder (MDD), particularly for treatment-resistant cases. However, identifying translatable biomarkers predictive of treatment outcomes remains underexplored.Participants with treatment resistant depression from the TDBRAIN dataset underwent either high frequency rTMS (10 Hz) at the left dorsolateral prefrontal cortex (DLPFC) (Protocol 1, n = 44) or low frequency rTMS (1 Hz) at the right DLPFC (Protocol 2, n = 73). Pre-treatment electroencephalograms (EEG) was collected, and changes in Beck Depression Inventory were measured post-treatment. EEG oscillations were decomposed into multiband intrinsic mode functions (IMF) and integrated under a latent space predictive modeling framework to identify signatures for predicting treatment outcomes.Multiband signatures significantly predicted rTMS outcomes (Protocol 1: r = 0.40, p < 0.01; Protocol 2: r = 0.26, p < 0.05). Key spatial patterns linked to treatment outcomes were identified, revealing three main oscillations: IMF-Alpha, IMF-Beta, and the residual signal. In Protocol 1, critical regions included the left frontal and parietal regions for IMF-Alpha, left frontal-central and right parietal regions for IMF-Beta, and bi-hemispheric central and left parietal-occipital regions for residual signals. In Protocol 2, critical regions involved the left frontal and parietal regions for IMF-Alpha, left frontal-central region IMF-Beta, and right frontal, left frontal-central, midline central, and left parietal-occipital regions for residual signals. These oscillatory features also showed correlations with specific personality measures, suggesting their potential clinical relevance.Our findings demonstrate the promise of machine learning-driven multiband EEG signatures for personalized MDD treatment prediction, offering a translatable pathway for improved patient outcomes.

    View details for DOI 10.1016/j.jad.2025.119483

    View details for PubMedID 40441660

  • Deep graph learning of multimodal brain networks defines treatment-predictive signatures in major depression. Molecular psychiatry Jiao, Y., Zhao, K., Wei, X., Carlisle, N. B., Keller, C. J., Oathes, D. J., Fonzo, G. A., Zhang, Y. 2025

    Abstract

    Major depressive disorder (MDD) presents a substantial health burden with low treatment response rates. Predicting antidepressant efficacy is challenging due to MDD's complex and varied neuropathology. Identifying biomarkers for antidepressant treatment requires thorough analysis of clinical trial data. Multimodal neuroimaging, combined with advanced data-driven methods, can enhance our understanding of the neurobiological processes influencing treatment outcomes. To address this, we analyzed resting-state fMRI and EEG connectivity data from 130 patients treated with sertraline and 135 patients with placebo from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study. A deep learning framework was developed using graph neural networks to integrate data-augmented connectivity and cross-modality correlation, aiming to predict individual symptom changes by revealing multimodal brain network signatures. The results showed that our model demonstrated promising prediction accuracy, with an R2 value of 0.24 for sertraline and 0.20 for placebo. It also exhibited potential in transferring predictions using only EEG. Key brain regions identified for predicting sertraline response included the inferior temporal gyrus (fMRI) and posterior cingulate cortex (EEG), while for placebo response, the precuneus (fMRI) and supplementary motor area (EEG) were critical. Additionally, both modalities identified the superior temporal gyrus and posterior cingulate cortex as significant for sertraline response, while the anterior cingulate cortex and postcentral gyrus were common predictors in the placebo arm. Additionally, variations in the frontoparietal control, ventral attention, dorsal attention, and limbic networks were notably associated with MDD treatment. By integrating fMRI and EEG, our study established novel multimodal brain network signatures to predict individual responses to sertraline and placebo in MDD, providing interpretable neural circuit patterns that may guide future targeted interventions. Trial Registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC) ClinicalTrials.gov Identifier: NCT#01407094.

    View details for DOI 10.1038/s41380-025-02974-6

    View details for PubMedID 40164695

    View details for PubMedCentralID 6100771

  • Multiband EEG signature decoded using machine learning for predicting rTMS treatment response in major depression. medRxiv : the preprint server for health sciences Arteaga, A., Tong, X., Zhao, K., Carlisle, N. B., Oathes, D. J., Fonzo, G. A., Keller, C. J., Zhang, Y. 2024

    Abstract

    Major depressive disorder (MDD) is a global health challenge with high prevalence. Further, many diagnosed with MDD are treatment resistant to traditional antidepressants. Repetitive transcranial magnetic stimulation (rTMS) offers promise as an alternative solution, but identifying objective biomarkers for predicting treatment response remains underexplored. Electroencephalographic (EEG) recordings are a cost-effective neuroimaging approach, but traditional EEG analysis methods often do not consider patient-specific variations and fail to capture complex neuronal dynamics. To address this, we propose a data-driven approach combining iterated masking empirical mode decomposition (itEMD) and sparse Bayesian learning (SBL). Our results demonstrated significant prediction of rTMS outcomes using this approach (Protocol 1: r=0.40, p<0.01; Protocol 2: r=0.26, p<0.05). From the decomposition, we obtained three key oscillations: IMF-Alpha, IMF-Beta, and the remaining residue. We also identified key spatial patterns associated with treatment outcomes for two rTMS protocols: for Protocol 1 (10Hz left DLPFC), important areas include the left frontal and parietal regions, while for Protocol 2 (1Hz right DLPFC), the left and frontal, left parietal regions are crucial. Additionally, our exploratory analysis found few significant correlations between oscillation specific predictive features and personality measures. This study highlights the potential of machine learning-driven EEG analysis for personalized MDD treatment prediction, offering a pathway for improved patient outcomes.

    View details for DOI 10.1101/2024.09.22.24314146

    View details for PubMedID 39399007

    View details for PubMedCentralID PMC11469383

  • Dementia Subtypes Defined Through Neuropsychiatric Symptom-Associated Brain Connectivity Patterns. JAMA network open Zhao, K., Xie, H., Fonzo, G. A., Carlisle, N. B., Osorio, R. S., Zhang, Y. 2024; 7 (7): e2420479

    Abstract

    Understanding the heterogeneity of neuropsychiatric symptoms (NPSs) and associated brain abnormalities is essential for effective management and treatment of dementia.To identify dementia subtypes with distinct functional connectivity associated with neuropsychiatric subsyndromes.Using data from the Open Access Series of Imaging Studies-3 (OASIS-3; recruitment began in 2005) and Alzheimer Disease Neuroimaging Initiative (ADNI; recruitment began in 2004) databases, this cross-sectional study analyzed resting-state functional magnetic resonance imaging (fMRI) scans, clinical assessments, and neuropsychological measures of participants aged 42 to 95 years. The fMRI data were processed from July 2022 to February 2024, with secondary analysis conducted from August 2022 to March 2024. Participants without medical conditions or medical contraindications for MRI were recruited.A multivariate sparse canonical correlation analysis was conducted to identify functional connectivity-informed NPS subsyndromes, including behavioral and anxiety subsyndromes. Subsequently, a clustering analysis was performed on obtained latent connectivity profiles to reveal neurophysiological subtypes, and differences in abnormal connectivity and phenotypic profiles between subtypes were examined.Among 1098 participants in OASIS-3, 177 individuals who had fMRI and at least 1 NPS at baseline were included (78 female [44.1%]; median [IQR] age, 72 [67-78] years) as a discovery dataset. There were 2 neuropsychiatric subsyndromes identified: behavioral (r = 0.22; P = .002; P for permutation = .007) and anxiety (r = 0.19; P = .01; P for permutation = .006) subsyndromes from connectivity NPS-associated latent features. The behavioral subsyndrome was characterized by connections predominantly involving the default mode (within-network contribution by summed correlation coefficients = 54) and somatomotor (within-network contribution = 58) networks and NPSs involving nighttime behavior disturbance (R = -0.29; P < .001), agitation (R = -0.28; P = .001), and apathy (R = -0.23; P = .007). The anxiety subsyndrome mainly consisted of connections involving the visual network (within-network contribution = 53) and anxiety-related NPSs (R = 0.36; P < .001). By clustering individuals along these 2 subsyndrome-associated connectivity latent features, 3 subtypes were found (subtype 1: 45 participants; subtype 2: 43 participants; subtype 3: 66 participants). Patients with dementia of subtype 3 exhibited similar brain connectivity and cognitive behavior patterns to those of healthy individuals. However, patients with dementia of subtypes 1 and 2 had different dysfunctional connectivity profiles involving the frontoparietal control network (FPC) and somatomotor network (the difference by summed z values was 230 within the SMN and 173 between the SMN and FPC for subtype 1 and 473 between the SMN and visual network for subtype 2) compared with those of healthy individuals. These dysfunctional connectivity patterns were associated with differences in baseline dementia severity (eg, the median [IQR] of the total score of NPSs was 2 [2-7] for subtype 3 vs 6 [3-8] for subtype 1; P = .04 and 5.5 [3-11] for subtype 2; P = .03) and longitudinal progression of cognitive impairment and behavioral dysfunction (eg, the overall interaction association between time and subtypes to orientation was F = 4.88; P = .008; using the time × subtype 3 interaction item as the reference level: β = 0.05; t = 2.6 for time × subtype 2; P = .01). These findings were further validated using a replication dataset of 193 participants (127 female [65.8%]; median [IQR] age, 74 [69-77] years) consisting of 154 newly released participants from OASIS-3 and 39 participants from ADNI.These findings may provide a novel framework to disentangle the neuropsychiatric and brain functional heterogeneity of dementia, offering a promising avenue to improve clinical management and facilitate the timely development of targeted interventions for patients with dementia.

    View details for DOI 10.1001/jamanetworkopen.2024.20479

    View details for PubMedID 38976268

    View details for PubMedCentralID PMC11231801

  • Optimizing Antidepressant Efficacy: Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response. medRxiv : the preprint server for health sciences Tong, X., Zhao, K., Fonzo, G. A., Xie, H., Carlisle, N. B., Keller, C. J., Oathes, D. J., Sheline, Y., Nemeroff, C. B., Williams, L. M., Trivedi, M., Etkin, A., Zhang, Y. 2024

    Abstract

    Major depressive disorder (MDD) is a common and often severe condition that profoundly diminishes quality of life for individuals across ages and demographic groups. Unfortunately, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates in a substantial number of patients. The development of effective therapies for MDD is hindered by the insufficiently understood heterogeneity within the disorder and its elusive underlying mechanisms. To address these challenges, we present a target-oriented multimodal fusion framework that robustly predicts antidepressant response by integrating structural and functional connectivity data (sertraline: R2 = 0.31; placebo: R2 = 0.22). Through the model, we identify multimodal neuroimaging biomarkers of antidepressant response and observe that sertraline and placebo show distinct predictive patterns. We further decompose the overall predictive patterns into constitutive network constellations with generalizable structural-functional co-variation, which exhibit treatment-specific association with personality traits and behavioral/cognitive task performance. Our innovative and interpretable multimodal framework provides novel insights into the intricate neuropsychopharmacology of antidepressant treatment and paves the way for advances in precision medicine and development of more targeted antidepressant therapeutics.

    View details for DOI 10.1101/2024.04.11.24305583

    View details for PubMedID 38645124

    View details for PubMedCentralID PMC11030479

  • Discriminative functional connectivity signature of cocaine use disorder links to rTMS treatment response. Nature. Mental health Zhao, K., Fonzo, G. A., Xie, H., Oathes, D. J., Keller, C. J., Carlisle, N. B., Etkin, A., Garza-Villarreal, E. A., Zhang, Y. 2024; 2 (4): 388-400

    Abstract

    Cocaine use disorder (CUD) is prevalent, and repetitive transcranial magnetic stimulation (rTMS) shows promise in reducing cravings. However, the association between a consistent CUD-specific functional connectivity signature and treatment response remains unclear. Here we identify a validated functional connectivity signature from functional magnetic resonance imaging to discriminate CUD, with successful independent replication. We found increased connectivity within the visual and dorsal attention networks and between the frontoparietal control and ventral attention networks, alongside reduced connectivity between the default mode and limbic networks in patients with CUD. These connections were associated with drug use history and cognitive impairments. Using data from a randomized clinical trial, we also established the prognostic value of these functional connectivities for rTMS treatment outcomes in CUD, especially involving the frontoparietal control and default mode networks. Our findings reveal insights into the neurobiological mechanisms of CUD and link functional connectivity biomarkers with rTMS treatment response, offering potential targets for future therapeutic development.

    View details for DOI 10.1038/s44220-024-00209-1

    View details for PubMedID 39279909

    View details for PubMedCentralID PMC11394333

  • Symptom dimensions of resting-state electroencephalographic functional connectivity in autism. Nature. Mental health Tong, X., Xie, H., Fonzo, G. A., Zhao, K., Satterthwaite, T. D., Carlisle, N. B., Zhang, Y. 2024; 2 (3): 287-298

    Abstract

    Autism spectrum disorder (ASD) is a common neurodevelopmental disorder characterized by social and communication deficits (SCDs), restricted and repetitive behaviors (RRBs) and fixated interests. Despite its prevalence, development of effective therapy for ASD is hindered by its symptomatic and neurophysiological heterogeneities. To comprehensively explore these heterogeneities, we developed a new analytical framework combining contrastive learning and sparse canonical correlation analysis that identifies symptom-linked resting-state electroencephalographic connectivity dimensions within 392 ASD samples. We present two dimensions with multivariate connectivity basis exhibiting significant correlations with SCD and RRB, confirm their robustness through cross-validation and demonstrate their conceptual generalizability using an independent dataset (n = 222). Specifically, the right inferior parietal lobe is the core region for RRB, while connectivity between the left angular gyrus and the right middle temporal gyrus show key contribution to SCD. These findings provide a promising avenue to parse ASD heterogeneity with high clinical translatability, paving the way for ASD treatment development and precision medicine.

    View details for DOI 10.1038/s44220-023-00195-w

    View details for PubMedID 39219688

    View details for PubMedCentralID PMC11361313

  • Early prediction of dementia using fMRI data with a graph convolutional network approach. Journal of neural engineering Han, S., Sun, Z., Zhao, K., Duan, F., Caiafa, C. F., Zhang, Y., Solé-Casals, J. 2024; 21 (1)

    Abstract

    Objective. Alzheimer's disease is a progressive neurodegenerative dementia that poses a significant global health threat. It is imperative and essential to detect patients in the mild cognitive impairment (MCI) stage or even earlier, enabling effective interventions to prevent further deterioration of dementia. This study focuses on the early prediction of dementia utilizing Magnetic Resonance Imaging (MRI) data, using the proposed Graph Convolutional Networks (GCNs).Approach. Specifically, we developed a functional connectivity (FC) based GCN framework for binary classifications using resting-state fMRI data. We explored different types and processing methods of FC and evaluated the performance on the OASIS-3 dataset. We developed the GCN model for two different purposes: (1) MCI diagnosis: classifying MCI from normal controls (NCs); and (2) dementia risk prediction: classifying NCs from subjects who have the potential for developing MCI but have not been clinically diagnosed as MCI.Main results. The results of the experiments revealed several important findings: First, the proposed GCN outperformed both the baseline GCN and Support Vector Machine (SVM). It achieved the best average accuracy of 80.3% (11.7% higher than the baseline GCN and 23.5% higher than SVM) and the highest accuracy of 91.2%. Secondly, the GCN framework with (absolute) individual FC performed slightly better than that with global FC generally. However, GCN using global graphs with appropriate connectivity can achieve equivalent or superior performance to individual graphs in some cases, which highlights the significance of suitable connectivity for achieving performance. Additionally, the results indicate that the self-network connectivity of specific brain network regions (such as default mode network, visual network, ventral attention network and somatomotor network) may play a more significant role in GCN classification.Significance. Overall, this study offers valuable insights into the application of GCNs in brain analysis and early diagnosis of dementia. This contributes significantly to the understanding of MCI and has substantial potential for clinical applications in early diagnosis and intervention for dementia and other neurodegenerative diseases. Our code for GCN implementation is available at:https://github.com/Shuning-Han/FC-based-GCN.

    View details for DOI 10.1088/1741-2552/ad1e22

    View details for PubMedID 38215493

  • Individualized fMRI connectivity defines signatures of antidepressant and placebo responses in major depression. Molecular psychiatry Zhao, K., Xie, H., Fonzo, G. A., Tong, X., Carlisle, N., Chidharom, M., Etkin, A., Zhang, Y. 2023; 28 (6): 2490-2499

    Abstract

    Though sertraline is commonly prescribed in patients with major depressive disorder (MDD), its superiority over placebo is only marginal. This is in part due to the neurobiological heterogeneity of the individuals. Characterizing individual-unique functional architecture of the brain may help better dissect the heterogeneity, thereby defining treatment-predictive signatures to guide personalized medication. In this study, we investigate whether individualized brain functional connectivity (FC) can define more predictable signatures of antidepressant and placebo treatment in MDD. The data used in the present work were collected by the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study. Patients (N = 296) were randomly assigned to antidepressant sertraline or placebo double-blind treatment for 8 weeks. The whole-brain FC networks were constructed from pre-treatment resting-state functional magnetic resonance imaging (rs-fMRI). Then, FC was individualized by removing the common components extracted from the raw baseline FC to train regression-based connectivity predictive models. With individualized FC features, the established prediction models successfully identified signatures that explained 22% variance for the sertraline group and 31% variance for the placebo group in predicting HAMD17 change. Compared with the raw FC-based models, the individualized FC-defined signatures significantly improved the prediction performance, as confirmed by cross-validation. For sertraline treatment, predictive FC metrics were predominantly located in the left middle temporal cortex and right insula. For placebo, predictive FC metrics were primarily located in the bilateral cingulate cortex and left superior temporal cortex. Our findings demonstrated that through the removal of common FC components, individualization of FC metrics enhanced the prediction performance compared to raw FC. Associated with previous MDD clinical studies, our identified predictive biomarkers provided new insights into the neuropathology of antidepressant and placebo treatment.

    View details for DOI 10.1038/s41380-023-01958-8

    View details for PubMedID 36732585

    View details for PubMedCentralID 5623437

  • A generalizable functional connectivity signature characterizes brain dysfunction and links to rTMS treatment response in cocaine use disorder. medRxiv : the preprint server for health sciences Zhao, K., Fonzo, G. A., Xie, H., Oathes, D. J., Keller, C. J., Carlisle, N., Etkin, A., Garza-Villarreal, E. A., Zhang, Y. 2023

    Abstract

    Cocaine use disorder (CUD) is a prevalent substance abuse disorder, and repetitive transcranial magnetic stimulation (rTMS) has shown potential in reducing cocaine cravings. However, a robust and replicable biomarker for CUD phenotyping is lacking, and the association between CUD brain phenotypes and treatment response remains unclear. Our study successfully established a cross-validated functional connectivity signature for accurate CUD phenotyping, using resting-state functional magnetic resonance imaging from a discovery cohort, and demonstrated its generalizability in an independent replication cohort. We identified phenotyping FCs involving increased connectivity between the visual network and dorsal attention network, and between the frontoparietal control network and ventral attention network, as well as decreased connectivity between the default mode network and limbic network in CUD patients compared to healthy controls. These abnormal connections correlated significantly with other drug use history and cognitive dysfunctions, e.g., non-planning impulsivity. We further confirmed the prognostic potential of the identified discriminative FCs for rTMS treatment response in CUD patients and found that the treatment-predictive FCs mainly involved the frontoparietal control and default mode networks. Our findings provide new insights into the neurobiological mechanisms of CUD and the association between CUD phenotypes and rTMS treatment response, offering promising targets for future therapeutic development.

    View details for DOI 10.1101/2023.04.21.23288948

    View details for PubMedID 37162878

    View details for PubMedCentralID PMC10168499

  • A dynamic graph convolutional neural network framework reveals new insights into connectome dysfunctions in ADHD. NeuroImage Zhao, K., Duka, B., Xie, H., Oathes, D. J., Calhoun, V., Zhang, Y. 2022; 246: 118774

    Abstract

    The pathological mechanism of attention deficit hyperactivity disorder (ADHD) is incompletely specified, which leads to difficulty in precise diagnosis. Functional magnetic resonance imaging (fMRI) has emerged as a common neuroimaging technique for studying the brain functional connectome. Most existing methods that have either ignored or simply utilized graph structure, do not fully leverage the potentially important topological information which may be useful in characterizing brain disorders. There is a crucial need for designing novel and efficient approaches which can capture such information. To this end, we propose a new dynamic graph convolutional network (dGCN), which is trained with sparse brain regional connections from dynamically calculated graph features. We also develop a novel convolutional readout layer to improve graph representation. Our extensive experimental analysis demonstrates significantly improved performance of dGCN for ADHD diagnosis compared with existing machine learning and deep learning methods. Visualizations of the salient regions of interest (ROIs) and connectivity based on informative features learned by our model show that the identified functional abnormalities mainly involve brain regions in temporal pole, gyrus rectus, and cerebellar gyri from temporal lobe, frontal lobe, and cerebellum, respectively. A positive correlation was further observed between the identified connectomic abnormalities and ADHD symptom severity. The proposed dGCN model shows great promise in providing a functional network-based precision diagnosis of ADHD and is also broadly applicable to brain connectome-based study of mental disorders.

    View details for DOI 10.1016/j.neuroimage.2021.118774

    View details for PubMedID 34861391

    View details for PubMedCentralID PMC10569447

  • Modified GAN Augmentation Algorithms for the MRI-Classification of Myocardial Scar Tissue in Ischemic Cardiomyopathy FRONTIERS IN CARDIOVASCULAR MEDICINE Sharma, U. C., Zhao, K., Mentkowski, K., Sonkawade, S. D., Karthikeyan, B., Lang, J. K., Ying, L. 2021; 8: 726943

    Abstract

    Contrast-enhanced cardiac magnetic resonance imaging (MRI) is routinely used to determine myocardial scar burden and make therapeutic decisions for coronary revascularization. Currently, there are no optimized deep-learning algorithms for the automated classification of scarred vs. normal myocardium. We report a modified Generative Adversarial Network (GAN) augmentation method to improve the binary classification of myocardial scar using both pre-clinical and clinical approaches. For the initial training of the MobileNetV2 platform, we used the images generated from a high-field (9.4T) cardiac MRI of a mouse model of acute myocardial infarction (MI). Once the system showed 100% accuracy for the classification of acute MI in mice, we tested the translational significance of this approach in 91 patients with an ischemic myocardial scar, and 31 control subjects without evidence of myocardial scarring. To obtain a comparable augmentation dataset, we rotated scar images 8-times and control images 72-times, generating a total of 6,684 scar images and 7,451 control images. In humans, the use of Progressive Growing GAN (PGGAN)-based augmentation showed 93% classification accuracy, which is far superior to conventional automated modules. The use of other attention modules in our CNN further improved the classification accuracy by up to 5%. These data are of high translational significance and warrant larger multicenter studies in the future to validate the clinical implications.

    View details for DOI 10.3389/fcvm.2021.726943

    View details for Web of Science ID 000699802200001

    View details for PubMedID 34589528

    View details for PubMedCentralID PMC8473636